Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: GlobeNewswire
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The updated guidelines recommend women undergo biennial mammography screening beginning at the age of 40 until the age of 74. The change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality. The announced changes from USPSTF also come in advance of a September 2024 deadline mandated by U.S. FDA requiring mammogram facilities to provide women with detailed information regarding their breast density, as part of routine mammogra
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
ATOS
Sec Filings
- 5/14/24 - Form DEL
- 5/13/24 - Form S-3
- 5/13/24 - Form 10-Q
- ATOS's page on the SEC website